Compare Stocks: INTS, FLNA, GRCE, and VERU

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FLNA Cassava Sciences	$1.04 +7.3%	$0.88	$0.67 ▼ $4.98	$50.00M	-0.65	1.03 million shs	769,137 shs
GRCE Grace Therapeutics	$2.04 -0.2%	$2.15	$1.79 ▼ $5.18	$42.82M	0.33	382,006 shs	32,255 shs
INTS Intensity Therapeutics	$3.33 +3.7%	$4.13	$3.21 ▼ $43.50	$10.85M	2.81	40,132 shs	10,689 shs
VERU Veru	$2.52 -1.0%	$2.52	$2.05 ▼ $7.33	$42.88M	-1.21	735,611 shs	62,560 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FLNA Cassava Sciences	+8.92%	+24.87%	+12.56%	-21.54%	-69.84%
GRCE Grace Therapeutics	-5.12%	-5.56%	-2.86%	-13.92%	-33.55%
INTS Intensity Therapeutics	-4.75%	-17.48%	-21.13%	-24.29%	-50.42%
VERU Veru	-4.51%	+1.20%	-5.58%	-16.99%	-34.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FLNA Cassava Sciences	$1.04 +7.3%	$0.88	$0.67 ▼ $4.98	$50.00M	-0.65	1.03 million shs	769,137 shs
GRCE Grace Therapeutics	$2.04 -0.2%	$2.15	$1.79 ▼ $5.18	$42.82M	0.33	382,006 shs	32,255 shs
INTS Intensity Therapeutics	$3.33 +3.7%	$4.13	$3.21 ▼ $43.50	$10.85M	2.81	40,132 shs	10,689 shs
VERU Veru	$2.52 -1.0%	$2.52	$2.05 ▼ $7.33	$42.88M	-1.21	735,611 shs	62,560 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FLNA Cassava Sciences	+8.92%	+24.87%	+12.56%	-21.54%	-69.84%
GRCE Grace Therapeutics	-5.12%	-5.56%	-2.86%	-13.92%	-33.55%
INTS Intensity Therapeutics	-4.75%	-17.48%	-21.13%	-24.29%	-50.42%
VERU Veru	-4.51%	+1.20%	-5.58%	-16.99%	-34.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FLNA Cassava Sciences	2.00	Hold	$5.00	383.09% Upside
GRCE Grace Therapeutics	2.00	Hold	$6.00	194.84% Upside
INTS Intensity Therapeutics	2.80	Moderate Buy	$7.00	110.21% Upside
VERU Veru	2.33	Hold	$24.50	874.16% Upside

Current Analyst Ratings Breakdown

Latest INTS, FLNA, GRCE, and VERU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	FLNA Cassava Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	INTS Intensity Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $7.00
8/11/2026	INTS Intensity Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/3/2026	GRCE Grace Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/21/2026	INTS Intensity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/21/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	FLNA Cassava Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FLNA Cassava Sciences	N/A	N/A	N/A	N/A	$1.54 per share	N/A
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	$3.99 per share	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	$4.94 per share	N/A
VERU Veru	$16.89M	2.54	N/A	N/A	$1.25 per share	2.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FLNA Cassava Sciences	-$90.97M	-$0.87	N/A	N/A	N/A	N/A	-58.78%	-36.74%	N/A
GRCE Grace Therapeutics	-$7.79M	-$1.18	N/A	N/A	N/A	N/A	-36.11%	-34.39%	11/12/2026 (Estimated)
INTS Intensity Therapeutics	-$11.61M	-$3.57	N/A	N/A	N/A	N/A	-116.61%	-94.01%	11/5/2026 (Estimated)
VERU Veru	-$22.73M	-$0.69	N/A	N/A	N/A	N/A	-47.58%	-35.83%	11/26/2026 (Estimated)

Latest INTS, FLNA, GRCE, and VERU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	GRCE Grace Therapeutics	-$0.1293	-$0.91	-$0.7807	-$0.91	$0.40 million	N/A
8/11/2026	Q2 2026	INTS Intensity Therapeutics	-$0.8725	-$1.11	-$0.2375	-$1.11	N/A	N/A
8/10/2026	Q3 2026	VERU Veru	-$0.32	-$0.30	+$0.02	-$0.30	$1.70 million	N/A
7/29/2026	Q2 2026	FLNA Cassava Sciences	N/A	-$0.18	N/A	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FLNA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	N/A
VERU Veru	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FLNA Cassava Sciences	N/A	2.08	2.08
GRCE Grace Therapeutics	N/A	11.47	11.47
INTS Intensity Therapeutics	0.01	5.00	5.00
VERU Veru	N/A	4.42	4.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FLNA Cassava Sciences	38.05%
GRCE Grace Therapeutics	6.08%
INTS Intensity Therapeutics	3.74%
VERU Veru	47.16%

Insider Ownership

Company	Insider Ownership
FLNA Cassava Sciences	4.60%
GRCE Grace Therapeutics	10.84%
INTS Intensity Therapeutics	7.60%
VERU Veru	14.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FLNA Cassava Sciences	30	48.31 million	46.09 million	Optionable
GRCE Grace Therapeutics	5	21.04 million	18.76 million	N/A
INTS Intensity Therapeutics	2,021	3.26 million	3.02 million	Not Optionable
VERU Veru	230	17.05 million	14.63 million	Optionable

INTS, FLNA, GRCE, and VERU Headlines

Recent News About These Companies

Veru (NASDAQ:VERU) Rating Lowered to "Sell" at Wall Street Zen

September 27, 2026 | americanbankingnews.com

Veru Advances Sabizabulin Toward Phase 2b Trial In Daraxonrasib-Resistant Pancreatic Cancer

September 8, 2026 | rttnews.com

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant ...

September 8, 2026 | finance.yahoo.com

Veru refocuses sabizabulin on post-daraxonrasib oncology

September 8, 2026 | tipranks.com

Veru Inc. Announces Sabizabulin Overcomes Daraxonrasib Resistance in Preclinical Pancreatic Cancer Studies and Advances Phase 2b Development Plan

September 8, 2026 | quiverquant.comQ

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

September 8, 2026 | globenewswire.com

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

September 2, 2026 | globenewswire.com

Veru (VERU) Q3 2026 Earnings Call Transcript

August 17, 2026 | finance.yahoo.com

Veru targets Q1 2027 PLATEAU interim analysis after enrolling 239 patients

August 10, 2026 | seekingalpha.com

Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239

August 10, 2026 | quiverquant.comQ

Veru Inc. Reports Full Enrollment of Phase 2b PLATEAU Trial of Enobosarm and Semaglutide Combination and Reaffirms Q1 2027 Interim Data Timeline

August 10, 2026 | quiverquant.comQ

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

August 10, 2026 | globenewswire.com

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

August 4, 2026 | globenewswire.com

Veru Inc. Announces August 10, 2026 Conference Call to Discuss Fiscal Third Quarter Results and Business Update

August 3, 2026 | quiverquant.comQ

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

August 3, 2026 | globenewswire.com

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

July 30, 2026 | globenewswire.com

Veru Inc. Announces Full Enrollment in Phase 2b PLATEAU Trial of Enobosarm in Older Patients With Obesity

July 27, 2026 | quiverquant.comQ

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

July 27, 2026 | globenewswire.com

Palisade's Dan Veru talks his small cap trading playbook

July 12, 2026 | cnbc.com

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

July 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INTS, FLNA, GRCE, and VERU Company Descriptions

Cassava Sciences NASDAQ:FLNA

$1.03 +0.07 (+7.25%)

As of 12:51 PM Eastern

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Grace Therapeutics NASDAQ:GRCE

$2.04 -0.01 (-0.25%)

As of 01:06 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Intensity Therapeutics NASDAQ:INTS

$3.33 +0.12 (+3.74%)

As of 01:06 PM Eastern

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Veru NASDAQ:VERU

$2.52 -0.03 (-0.98%)

As of 01:07 PM Eastern

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INTS, FLNA, GRCE, and VERU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INTS, FLNA, GRCE, and VERU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INTS, FLNA, GRCE, and VERU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INTS, FLNA, GRCE, and VERU Company Descriptions

Cassava Sciences NASDAQ:FLNA

Grace Therapeutics NASDAQ:GRCE

Intensity Therapeutics NASDAQ:INTS

Veru NASDAQ:VERU

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INTS, FLNA, GRCE, and VERU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INTS, FLNA, GRCE, and VERU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INTS, FLNA, GRCE, and VERU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INTS, FLNA, GRCE, and VERU Company Descriptions

Cassava Sciences NASDAQ:FLNA

Grace Therapeutics NASDAQ:GRCE

Intensity Therapeutics NASDAQ:INTS

Veru NASDAQ:VERU

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools